[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646908":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":22,"locations":27,"responsibleParty":45,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":9,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JAB-8263","EXPERIMENTAL",null,[13],"Drug: JAB-8263",[15,19],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Variable dose1, orally Q2D with 28 days",[9],{"type":16,"name":9,"description":20,"armGroupLabels":21,"otherNames":11},"Variable dose2, orally Q2D with 28 days",[9],[23],{"name":24,"role":25,"phone":11,"phoneExt":11,"email":26},"Jun Yang Jun Project Director","CONTACT","clinicaltrials@jacobiopharma.com",[28],{"facility":29,"status":11,"city":30,"state":31,"zip":11,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Beijing Hospital","Beijing","Beijing Municipality","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":25,"phone":43,"phoneExt":11,"email":44},"Xuan Dr. Zhang","+86 010-58115094","zxlab@outlook.com",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100646908","phase-2-a-phase-iia-study-of-jab-8263-in-patients-with-active-rheumatoid-arthritis-100646908",false,"NCT07684157","A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis","A Phase Randomized, Double-blind, Placebo-controlled Evaluate the Efficacy and Safety IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Age ≥18 years old and \\\u003C75 years old at the time of signing the informed consent form, regardless of gender;\n2. Active rheumatoid arthritis, ESR or C-reactive protein\\> upper limit of normal\n3. Meets the 2010 American College of Rheumatology ACR\u002FEULAR RA classification standards\n4. Participants have recovered from adverse reactions to previous antirheumatic treatment.\n\nExclusion Criteria:\n\n1. Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin;\n2. Use of NSAIDs within 1 week before first dose of investigational product\n3. Known or suspected allergies to the investigational product or any of its components;\n4. Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years);\n5. Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;","ALL","18 Years","75 Years",{"count":58,"type":59},32,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK\u002FPD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.",[65],"Rheumatoid Arthritis (RA)","NOT_YET_RECRUITING","2026-06-29",{"date":69,"type":70},"2026-07-06","ACTUAL",{"date":72,"type":59},"2026-07-29",{"date":74,"type":59},"2027-12-31",{"name":5,"class":6},1]